Endothelin receptor remodeling induces the portal venous hyper-response to endothelin-1 following endotoxin pretreatment

• Published in: Shock (Augusta, Ga.) Ga.), 2002, Vol.17 (1), p.36-40
• Main Authors: YOKOYAMA, Yukihiro, BAVEJA, Rajiv, KRESGE, Nicole, SONIN, Natalie, NAKANISHI, Kazuya, ZHANG, Jian X, GITZELMANN, Christopher A, CLEMENS, Mark G
• Format: Article
• Language: English
• Subjects: Anesthesia. Intensive care medicine. Transfusions. Cell therapy and gene therapy; Animals; Biological and medical sciences; Emergency and intensive care: infection, septic shock; Endothelin Receptor Antagonists; Endothelin-1 - metabolism; Endothelin-1 - pharmacology; Endotoxins - pharmacology; Intensive care medicine; Kinetics; Lipopolysaccharides - pharmacology; Liver - blood supply; Liver - drug effects; Male; Medical sciences; Portal Pressure - drug effects; Portal Vein - drug effects; Portal Vein - physiopathology; Protein Binding; Rats; Rats, Sprague-Dawley; Receptors, Endothelin - agonists; Receptors, Endothelin - metabolism; Thermodynamics
• ISSN: 1073-2322; 1540-0514
• DOI: 10.1097/00024382-200201000-00007

The purpose of this study was to determine the changes in endothelin (ET) receptor subtype expression and their functional significance after endotoxin pretreatment. Rats were pretreated with lipopolysaccharide (LPS) or sterile saline (control). After 24 h, liver samples were homogenized and competitive receptor binding assays were performed. There was no significant difference in ET receptor binding affinity between the control and LPS groups. However, the receptor subtype density showed a significant increase in ET(B) receptors in LPS-treated rats, whereas the amount of ET(A) receptors was almost identical between the two groups. In control, almost all ET receptors (95%) were displaced by using combined ET(A) antagonist (BQ-610) and ET(B) agonist (IRL-1620) as competitors, whereas only 80% (P < 0.05 versus control) was displaced in LPS group, raising the possibility of novel type of ET receptor expression. An infusion of ET(B) agonist (Sarafotoxin 6c, S6c) through portal vein in isolated perfused livers produced the same pressure response in both LPS and control groups; however, the portal pressure increase in response to the ET-1, which binds all ET receptors, was significantly potentiated in LPS-treated rats compared to controls. We conclude that altered regulation of ET receptors, in particular, the appearance of ET binding capacity that is not displaced by ET(A) or ET(B) competitors, may explain the hyper-response of the portal venous system to ET-1 during endotoxemia.